IceCure Medical Ltd. (ICCM)
NASDAQ (CM) NASDAQ (CM) Primary Summary
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03.
IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript
IceCure Medical Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 89,496 | $816,293.02 | $296,231.76 | -$520,061.26 | -63.71% |
| BP Brett Pohl Kingdom Financial Group LLC | 528 | $4,815.89 | $1,716 | -$3,099.89 | -64.37% |
 Courtney Haddad Concurrent Investment Advisors, LLC | 2,583.4 | $47,761.99 | $7,440.21 | -$40,321.78 | -84.42% |
IceCure Medical Ltd. (ICCM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has IceCure Medical Ltd. ever had a stock split?
IceCure Medical Ltd. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Eyal Shamir CEO | NASDAQ (CM) Exchange | M53071136 CUSIP |
| IL Country | 69 Employees | - Last Dividend | 4 Jun 2026 Last Split | - IPO Date |
Overview
IceCure Medical Ltd is a pioneering company, with a focus on the development, manufacturing, and marketing of innovative cryoablation systems and technologies for the treatment of tumors. Founded in 2006 and based in Caesarea, Israel, this commercial stage medical device company has dedicated itself to advancing the field of minimally invasive treatments. Through its state-of-the-art technology, IceCure Medical strives to offer effective tumor treatment options, aiming to improve patient outcomes and quality of life. Their groundbreaking approach leverages the power of extreme cold, utilizing liquid nitrogen to destroy tumors by freezing, which presents a promising alternative to traditional surgery and other treatment methods.
Products and Services
- ProSense system
The ProSense system represents IceCure Medical's flagship technology, designed as a single probe system specifically for the targeted treatment of tumors. This system, along with its associated disposables, is engineered for precision and is acclaimed for its efficacy in treating various types of benign and malignant tumors. The ProSense system has gained recognition for its minimally invasive nature, offering patients a faster recovery time compared to conventional surgical treatments.
- IceSense3 system
IceCure Medical extends its cryoablation technology with the IceSense3 system, tailored for ablation treatments across a broad array of medical specialties including urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. This versatility underscores the system's adaptability and effectiveness in addressing tumors in different parts of the body, providing physicians with a versatile tool in their treatment arsenal.
- XSense system
In development is the XSense system, a single probe system that IceCure Medical is working on to expand its portfolio. While specific details and capabilities are under refinement, this system signifies IceCure Medical's continuous commitment to innovation and its vision to extend the benefits of cryoablation to a wider patient demographic.
- MultiSense
Another promising development is the MultiSense system, conceptualized to handle the treatment of multiple and larger tumors. This multi probe system is being designed to offer greater flexibility and efficiency, potentially setting new standards in the treatment of complex tumor cases. With MultiSense, IceCure Medical aims to address a significant need in oncology for effective, minimally invasive treatment options for patients with larger or multiple tumor burdens.
